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ABSTRACT
Background
The global spread of multidrug–resistant malaria parasites has led to an urgent need for new
chemotherapeutic agents. Drug discovery is primarily directed to the asexual blood stages, and
few drugs that are effective against the obligatory liver stages, from which the pathogenic
blood infection is initiated, have become available since primaquine was deployed in the 1950s.
Methods and Findings
Using bioassay-guided fractionation based on the parasite’s hepatic stage, we have isolated a
novel morphinan alkaloid, tazopsine, from a plant traditionally used against malaria in
Madagascar. This compound and readily obtained semisynthetic derivatives were tested for
inhibitory activity against liver stage development in vitro (P. falciparum and P. yoelii) and in
vivo (P. yoelii). Tazopsine fully inhibited the development of P. yoelii (50% inhibitory
concentration [IC50] 3.1 lM, therapeutic index [TI] 14) and P. falciparum (IC50 4.2 lM, TI 7)
hepatic parasites in cultured primary hepatocytes, with inhibition being most pronounced
during the early developmental stages. One derivative, N-cyclopentyl-tazopsine (NCP-
tazopsine), with similar inhibitory activity was selected for its lower toxicity (IC50 3.3 lM, TI
46, and IC50 42.4 lM, TI 60, on P. yoelii and P. falciparum hepatic stages in vitro, respectively).
Oral administration of NCP-tazopsine completely protected mice from a sporozoite challenge.
Unlike the parent molecule, the derivative was uniquely active against Plasmodium hepatic
stages.
Conclusions
A readily obtained semisynthetic derivative of a plant-derived compound, tazopsine, has
been shown to be specifically active against the liver stage, but inactive against the blood
forms of the malaria parasite. This unique specificity in an antimalarial drug severely restricts
the pressure for the selection of drug resistance to a parasite stage limited both in numbers
and duration, thus allowing researchers to envisage the incorporation of a true causal
prophylactic in malaria control programs.
The Editors’ Summary of this article follows the references.
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Malaria re-emerged abruptly in the highlands of Madagas-
car in the mid-1980s and was associated with large-scale
mortality and morbidity in the nonimmune inhabitants [1].
Shortage of antimalarial drugs, mainly chloroquine, led the
population to rely on traditional herbal remedies. In a
subsequent large-scale ethnobotanical survey, 229 plant
species, of which 30% are endemic to Madagascar, were
reported to possess antimalarial activity [2], although the
manner in which they are administered was not recorded.
One of the endemic plants, Strychnopsis thouarsii (Menisper-
maceae) [3,4], was selected for further investigations, because
it is the sole ingredient of a widely used remedy reputed to
provide protection speciﬁcally against malaria [5].
The traditional decoction, prepared simply by boiling S.
thouarsii stem bark in water, showed only weak activity in vitro
against the FcB1 strain of P. falciparum erythrocytic stages
(50% inhibitory concentration [IC50] 34.0 6 9.4 lg/ml). Given
that some medicinal preparations are also used as a
preventive (for example, during epidemics), we hypothesized
that this particular remedy, and others that are similarly
poorly active against the blood stage parasites, might actually
be active against the initial pre-erythrocytic (PE) phase of the
infection [6]. This phase represents the invasion of hepato-
cytes by the sporozoites inoculated by the mosquito and the
full development of the hepatic parasites from which the
pathogenic erythrocytic phase originates. Full inhibition of
the PE stages of the infection provides true causal prophy-
laxis whereby the blood stage infection and its associated
clinical manifestations would be totally prevented. For P.
vivax and P. ovale, in which dormant hepatic forms, the
hypnozoites, can give rise to relapses in humans, drugs active
against hypnozoites would provide a radical cure of the
infection. In drug discovery programs, routine screening for
anti-PE stage activity is seldom carried out, partly because
these stages are clinically silent, but mainly because access to
PE parasites is costly and restricted to a few laboratories. We
aimed to establish whether the traditional remedy prepared
from S. thouarsii contained agents active against Plasmodium
hepatic stages, and if so, to isolate them and explore their
suitability as future lead compounds.
Methods
Drugs
Tazopsine, [a]D
22  468 (c 0.5, MeOH) and HRCIMS m/z
350.1608 [MþH]
þ, was puriﬁed from Strychnopsis thouarsii stem
bark collected in the eastern rain forest of Madagascar at
Andasibe National Park. N-cyclopentyl-tazopsine (NCP-ta-
zopsine), [a]D
22  308 (c 0.03, MeOH) and HRCIMS m/z
418.2239 [MþH]
þ, was obtained from tazopsine by a classical
method of amine reductive alkylation [7]. Brieﬂy, 200 ll (2.3
mmol) of cyclopentanone and 150 mg (2.4 mmol) of sodium
cyanoborohydride (Fluka, Buchs, Switzerland) were added
successively to 700 mg (2 mmol) of tazopsine solubilized in 5
ml of absolute methanol and stirred at room temperature
under argon for 24 h. After removal of the solvent under
reduced pressure, the residue was acidiﬁed with 1 N HCl,
then basiﬁed with NH4OH, dried and puriﬁed by a silica gel
column chromatography eluted with dichloromethane–meth-
anol–20% ammonia (90-10-1). A total of 675 mg (1.62 mmol)
of NCP-tazopsine were obtained (81% yield). Primaquine was
purchased from Sigma (Saint-Quentin Fallavier, France).
In Vitro Assay for P. yoelii and P. falciparum Liver Stage
Inhibition
P. yoelii (265 BY strain) and P. falciparum (NF 54 strain)
sporozoites were obtained by dissection of infected Anopheles
stephensi salivary glands. Primary mouse hepatocytes were
isolated as previously described [8] and seeded in eight-well
Lab-Tek plastic chamber slides (VWR, Fontenay-sous-Bois,
France) previously coated with rat-tail collagen I (BD
Biosciences, Le Pont de Claix, France) at a density of 10
5
cells per well. Mouse hepatocytes were cultured at 37 8Ci n
5% CO2 in William’s E medium supplemented with 10% fetal
calf serum, 1% L-glutamine, 1% sodium pyruvate, 1%
insulin-transferrin-selenium, 1% nonessential amino acids,
and 1% penicillin-streptomycin (all from Invitrogen, Cergy-
Pontoise, France), for 24 h before inoculation of P. yoelii
sporozoites (10
5 per well). Human liver fragments were
collected following informed consent provided from patients
undergoing a partial hepatectomy. The collection and use of
these tissues were undertaken in accordance with French
Government ethical regulations. Primary human hepatocytes
were isolated from the healthy parts of these liver biopsies as
previously described [9]. Human hepatocytes were seeded in
LabTek plastic chamber slides coated with collagen, at a
density of 1.8310
5 cells per well and cultured at 37 8Ci n5 %
CO2 in the same medium as above, supplemented with 10
 7 M
dexamethasone (Sigma) and 2% DMSO after complete cell
adherence (12–24 h), for at least 48 h before inoculation of P.
falciparum sporozoites (10
5 per well). For a standard assay, the
plant extract, the puriﬁed compound, or primaquine was
solubilized in DMSO, further diluted in culture medium
(equal DMSO concentrations of ,0.3% per well), and then
added to hepatocyte cultures at the time of sporozoite
inoculation. Three hours later, after sporozoite penetration
into hepatocytes, cultures were washed and further incubated
in the presence of the drug. Culture medium containing the
appropriate drug concentration was changed daily until 48 h
for P. yoelii, or until 5 d for P. falciparum. Parasites were
quantiﬁed on the last day of incubation. For the in vitro
timing experiments, tazopsine treatment of P. yoelii and P.
falciparum cultures was undertaken for different periods
during the cultivation: 0 h to 3 h, 3 h to 24 h, or 24 h to 48
h after P. yoelii sporozoite inoculation (quantiﬁcation at 48 h),
or 0 h to 2 d, or 3 d to 5 d after P. falciparum sporozoite
inoculation (quantiﬁcation at 5 d). Parasite quantiﬁcation was
done by immunoﬂuorescence analysis following ﬁxation of
the cultures with cold methanol and parasite-speciﬁc staining
by a mouse polyclonal serum raised against the P. falciparum
heat shock protein 70 that also cross-reacts with the
homologous protein of P. yoelii, and revealed with FITC-
conjugated goat anti-mouse immunoglobulin (Sigma) [8].
Cells were stained with Evans Blue (0.4%), and parasites and
cells nuclei were stained with 1 lg/ml of diamidino-phenyl-
indole (DAPI; Sigma). Parasite numbers were counted under a
ﬂuorescence microscope with a 253 light microscope
objective. IC50 values, the drug concentration at which a
50% reduction in the number of parasites was observed, as
compared to the number in the DMSO control cultures, were
derived from two independent experiments in which each
concentration was tested in triplicate wells.
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Primary hepatocytes of mice or humans were prepared as
above and seeded in 96-well plates coated with collagen, at a
density of 5 3 10
4 and 7 3 10
4 cells per well, respectively.
Drugs were added to the culture medium, which was changed
daily after 24 h or 48 h of incubation for mouse and human
hepatocytes, respectively. After 48 h of drug exposure (mouse
hepatocytes) or 5 d (human hepatocytes), 50 ll of neutral red
(Sigma) at 0.02% in phosphate-buffered saline (PBS) were
added per well and incubated for 24 additional hours [10].
Cultures were then washed with PBS and the neutral red
extracted with 1% SDS from viable cells and quantiﬁed by
measuring the OD540 on a microplate autoreader photometer
(BioTek Instruments, Winooski, Vermont, United States). The
50% toxic concentration (TC50) values, the drug concen-
tration at which a 50% reduction of red neutral incorpo-
ration was observed, as compared to that incorporated in the
DMSO control cultures, were derived from two independent
experiments in which each concentration was tested in
quadruplicate.
Statistical Methods for IC50 and TC50 Estimations
IC50 and TC50 were calculated by nonlinear regression
using four-parameter logistic curves on the SigmaPlot 10.0
software (http://www.systat.com). Each IC50 or TC50 is ex-
pressed as a mean between two independent experiments,
followed by the standard error of the mean.
In Vitro Assay for P. falciparum Blood Stages Inhibition
P. falciparum clone 3D7 (chloroquine sensitive) and clone
FCR3 (chloroquine resistant) erythrocytic stages were cul-
tured as described [11], and drug antiplasmodial activity was
assessed by the standard method [12] with minor modiﬁca-
tions. Brieﬂy, the compounds tazopsine and NCP-tazopsine
solubilized in DMSO were further diluted in RPMI before
adding to parasite cultures (0.5% parasitemia, mainly young
trophozoites, and 1.8% ﬁnal hematocrit), in a 2-fold dilution
series. Plates were maintained for 24 h at 37 8Ci n5 %C O 2.
Then 0.5 lCi of [
3H]-hypoxanthine was added to each well,
and cultures were incubated for a further 24 h. The growth
inhibition was determined by comparison of the radioactivity
incorporated into the treated cultures with that into the
control cultures, by liquid scintillation counting.
In Vivo Assay for Activity on P. yoelii Infections
All animal were kept and used in accordance with institu-
tional guidelines and European regulations. Female 6-wk-old
Swiss mice (Rene ´ Janvier, Le Genest-Saint-Isle, France)
weighing 24–31 g were randomly allotted to ﬁve groups.
The drug to be tested was administered orally. Tazopsine was
diluted in sterile water and NCP-tazopsine in sterile water
with 10% of Tween 80 (Aldrich, Le Chesnay, France). The
drugs were administrated on days  1, 0, þ1, þ2( þ40 h), and
the mice challenged on day 0 by retro-orbital injection of P.
yoelii (265 BY strain) sporozoites. Group 1 received 100 mg/kg/
day of tazopsine (n¼5), and group 2 received sterile water at
the same times (controls, n ¼ 5); groups 1 and 2 were
challenged with 4,000 sporozoites. Group 3 received 100 mg/
kg/d of NCP-tazopsine (n¼5), group 4 received 200 mg/kg/d of
NCP-tazopsine (n ¼ 8), and group 5 received 10% Tween in
sterile water (controls, n ¼ 5); groups 3, 4, and 5 were
challenged with 10,000 sporozoites. Parasites were enumer-
ated by blinded microscopic examination of Giemsa-stained
tail-blood smears collected from day 2 to day 23 post-
inoculation. A mouse was considered negative when no
parasites could be observed in 20,000 red blood cells (50 ﬁelds
under a 503 light microscope objective) on any day during
the period of observation. The results presented were derived
from two independent duplicate experiments.
In order to test for inhibitory activity against P. yoelii blood
stages, four groups of ﬁve naive mice were inoculated
(intraperitoneally) with 10
6 P. yoelii–infected red blood cells
on day 0. Three hours later, one group was treated with
tazopsine at 100 mg/kg, another with NCP-tazopsine at 200
mg/kg, whereas the other two groups acted as controls
(respectively, water and 10% Tween 80). The doses were
repeated daily until day þ3. For the group treated with NCP-
tazopsine and its control group, the animals were anesthe-
tised 2 h following the administration of the last dose (day
þ3), and placed for 30 min over a cage with 100 female
laboratory-bred A. stephensi. Oocysts were enumerated in 30
mosquito midguts dissected 8 d later, and the number of
sporozoites in the salivary glands dissected from 30 insects
was ascertained a further 7 d later. All the experiments were
performed in two independent duplicates, and enumeration
of parasites in blood smears and mosquitoes was conducted
in a blinded fashion.
Real-Time PCR Quantification of P. yoelii Parasites in
Mouse Livers
Female 6-wk-old Swiss mice weighing 24–31 g were
randomly allotted to three groups. The drug to be tested
was administrated orally on days  1, 0, and þ1. Group 1
received 100 mg/kg/d of NCP-tazopsine (n ¼ 4), group 2
received 200 mg/kg/d of NCP-tazopsine (n ¼ 6), whereas the
control group received Tween 80 at 10% in sterile water (n¼
5). Mice were challenged on day 0 by retro-orbital injection
with 120,000 P. yoelii sporozoites and sacriﬁced 42-h post-
inoculation. A piece of liver (0.2 g) was harvested and total
RNA extracted using the Micro to Midi kit (Invitrogen)
according to the manufacturer’s instructions. The detection
and quantiﬁcation of liver stage parasites were done as
described [13] with minor modiﬁcations. Five micrograms of
total RNA were treated with DNase from the Turbo DNA-free
kit (Ambion, Huntingdon, United Kingdom) and reverse
transcribed by Superscript II (Invitrogen) according to the
manufacturer’s instructions. A total of 6 ll of the 300 ll
obtained (an equivalent to 100 ng of the starting total RNA)
were used per TaqMan PCR assay (MX4000 multiplex
quantitative PCR system; Stratagene, La Jolla, California,
United States). Gene-speciﬁc P. yoelii primers (forward 59-
TTAGATTTTCTGGAGACAAACAACT, reverse 59-
TCCCTTAACTTTCGTTCTTGAT; Invitrogen) and a probe
(59-6FAM-CGAAAGCATTTGCCTAAAATACTTCCAT-
BHQ1; MWG Biotech, Ebersberg, Germany) were designed
from the P. yoelii 265BY 18S rRNA sequence using the Primer
Express software (PE Applied Biosystems, Courtaboeuf,
France). Lack of nonspeciﬁc ampliﬁcation with mouse
genomic DNA was determined in preliminary experiment
(unpublished data). Mouse b-actin primers (forward 59-
ACGGCCAGGTCATCACTATTG, reverse 59-CAAGAAG-
GAAGGCTGGAAAAG; Invitrogen) and a probe (59-HEX-
CAACGAGCGGTTCCGATGCCC-BHQ2; MWG Biotech)
were designed and used for normalization. Puriﬁed plasmids
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actin PCR fragments cloned with the TOPO TA cloning kit
(Invitrogen) were used in a 10-fold dilution series to obtain a
standard curve. All TaqMan test samples and plasmid stand-
ards were performed in triplicate. Absolute transcript copy
number for each gene was calculated based on their external
standard curves. For each sample, P. yoelii rRNA 18S absolute
copies were normalized to 10
6 copies of mouse b-actin.
Statistical Analysis
Statistical analysis was undertaken by one-way analysis of
variance (ANOVA) tests coupled to Tukey HSD tests; in this
latter test, the exact p-value is given only if it exceeds 0.01.
Results
The activity of the S. thouarsii decoction was assessed in a
standard bioassay of cultured mouse primary hepatocytes
infected with P. yoelii sporozoites [14,15]. Parasite inhibition
was observed in the exposed cultures (IC50 8.5 6 0.7 lg/ml),
with hepatic forms completely eliminated at concentrations
of 20 lg/ml or greater. Toxicity, as assessed by red neutral
incorporation into the uninfected primary hepatocytes, was
absent at the highest concentrations tested (100 lg/ml). In
order to identify the compound(s) responsible for this
activity, we conducted a bioassay-guided fractionation (Fig-
ure S1). The activity resided in the methanolic, but not the
ethanolic extract (consistent with a highly polar compound),
with an IC50 of 12.5 6 3.5 lg/ml. Successive chromatographic
separations, monitored by the in vitro P. yoelii liver stage
inhibition assays, led to the isolation of a pure active
compound that we named tazopsine which represented the
major constituent of the dry material obtained from the
traditional decoction (10.3% w/w) (Figure S2). The structure
of tazopsine was solved by two-dimensional
1H and
13C
nuclear magnetic resonance (NMR) spectroscopy (Table S1).
It consists of a morphinan skeleton bearing two methoxyl
groups at positions 3 and 8, and four hydroxyl groups at
positions 4, 6, 7, and 10 (Figure 1), with a molecular weight of
349. To the best of our knowledge, this structure had not
been previously described.
Antimalarial Activity of Tazopsine
Puriﬁed tazopsine was found to be active against the liver
stages of P. yoelii and those of P. falciparum. Total inhibition of
cultured P. yoelii hepatic stages was obtained at 7.1 lMo r
greater (IC50 3.1 6 0.1 lM) in cultured primary hepatocytes
(Figure 2A), yielding a therapeutic index (TI) of 14 (TC50 43.7
6 1.6 lM). For P. falciparum–infected primary human
hepatocyte cultures [9], parasite development was fully
inhibited at higher concentrations of 28 lM or greater (IC50
4.2 6 0.3 lM), and the corresponding TI using human
primary hepatocytes (TC50 28.4 6 4.3 lM) was 7 (Figure 2A).
Tazopsine was also active against the erythrocytic stages of P.
falciparum in vitro (IC50 4.7 6 0.9 lM using the 3D7 line, IC50
5.7 6 2.1 lM using the FCR3 line).
Examination of cultures subjected to suboptimal inhibitory
concentrations revealed that tazopsine inhibited growth
because the surviving hepatic parasites were signiﬁcantly
smaller than those observed in control cultures (Figure 2B
and 2C). In order to determine the point at which the liver
parasites were most susceptible to inhibition by tazopsine, we
exposed P. yoelii hepatic cultures to suboptimal inhibitory
concentrations at the different phases of the infection: the
ﬁrst 3 h postinfection (PI), by which time the sporozoites have
invaded the hepatocytes; from 3 to 24 h PI, at the end of
which, nuclear division has just been initiated in the growing
trophozoites; and ﬁnally, from 24 to 48 h PI when the
schizonts were maturing to large multinucleate forms.
Sporozoite invasion and differentiation into early hepatic
stages were not affected by tazopsine, nor did pretreatment
of sporozoites with tazopsine alter hepatocyte invasion
efﬁciency (Figure 3A). Inhibition was the most pronounced
during the early developmental stages of the hepatic parasite
(3 to 24 h), with only residual inhibitory activity on growing
young schizonts (24 to 48 h) (Figure 3A). In parallel experi-
ments, P. falciparum hepatic stages were similarly found to be
most susceptible to inhibition during the early stage of
trophozoite development (Figure 3B). For both parasite
species, the inhibitory effect was found to be dose dependent
(Figure 3). It should be pointed out that hepatic stages of P.
yoelii and P. falciparum differ in the time required for
maturation into forms containing invasive merozoites.
Figure 1. Structure of Tazopsine
Tazopine is shown on the left. The chemically modified substituents are indicated by asterisks (left): a single asterisk (*) indicates 4-OH protectedb y4 - O-
alkylations; double asterisks (**) indicate 6,7-diol protected by an acetonide ketal; and triple asterisks (***) indicate secondary amine substituted by N-
acetylation and N-alkylations. Structure of the semisynthetic alkaloid, NCP-tazopsine is shown on the right.
doi:10.1371/journal.pmed.0030513.g001
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and in 5.5 to 6 d for P. falciparum. For both species,
maturation takes longer in cultured primary hepatocytes.
Nonetheless, the P. yoelii model has been extensively used for
biological, immunological, and chemotherapeutical investi-
gations; and to a large extent, similar ﬁndings were observed
when the corresponding studies were carried out using P.
falciparum [16–18].
Hepatic Stage Specificity and Protective Efficacy of NCP-
Tazopsine
Preliminary experiments established that tazopsine was
toxic to mice at oral doses exceeding 100 mg/kg given daily
over 4 d (the standard number of doses in this malaria
model). Upon challenge with 4,000 P. yoelii sporozoites,
protection from infection was obtained in 70% of the mice
treated at 100 mg/kg daily for 4 d, whereas the remaining 30%
developed a blood stage parasitemia, albeit their prepatent
period (the time from inoculation until parasites become
microscopically detectable) was extended by about 4 d over
that of the controls (Figure 4). In order to determine whether
protection from infection might be in part due to an
additional effect of tazopsine on the blood stage parasite,
groups of mice were treated as above and challenged on day 0
with P. yoelii–infected blood. No signiﬁcant inhibition of the
erythrocytic multiplication cycle could be detected (unpub-
lished data). This conﬁrmed that the protection was due to an
inhibition of the hepatic stages.
The toxicity of tazopsine in mice and on cultured human
cells was of concern. We, therefore, synthesized a series of
derivatives from tazopsine, and those still found active
against cultured P. yoelii (IC50 , 50 lM), were tested for
toxicity. Of the seven substituents of tazopsine, four were
targeted because they were amenable to functionalization by
classical alkylation: the three hydroxyl groups at positions 4,
6, and 7, and the secondary amine (Figure 1). Whereas
alkylation of the three hydroxyl groups led to a complete loss
of activity, inhibition of liver stages was retained by seven of
the ten semisynthesized N-alkylated derivatives. Their IC50
values, determined using the hepatic P. yoelii inhibition assay,
ranged from 3.3 lMt o2 4lM. NCP-tazopsine had the lowest
IC50 (3.3 6 0.05 lM) and the lowest toxicity to cultured
primary mouse hepatocytes (TC50 150.5 6 9.5 lM). These
values are a signiﬁcant improvement on tazopsine, yielding a
TI of 46 for NCP-tazopsine (Figure 4A). Dose-dependent
inhibition of P. falciparum hepatic stages was also obtained
with NCP-tazopsine, with an IC50 of 42.4 lM and a TC50 for
primary human hepatocytes of 2,549.6 6 307.6 lM, resulting
in a TI of 60 (Figure 4A), again a more adequate value than
that of tazopsine. Furthermore, NCP-tazopsine did not have
any detectable effect on the multiplication in vitro–cultured
erythrocytic P. falciparum (both the 3D7 and the FCR3 lines)
up to concentrations of 600 lM. By way of comparison, the
activity of primaquine, the only drug licensed for use against
the parasite’s hepatic forms, has been determined in parallel
in the same model systems (Table 1). The IC50 for primaquine
is close to 1 lM for both parasite species, and although it is
signiﬁcantly more active than NCP-tazopsine on P. falciparum,
similar therapeutic indices were observed with the two
molecules for this parasite species.
Oral administration of NCP-tazopsine up to doses of 400
mg/kg for 4 d was not found to be toxic to mice. When mice
treated with daily 200 mg/kg doses over 4 d were challenged
with 10,000 P. yoelii sporozoites, none of the mice developed a
blood stage infection (Figure 4B). At subdoses of 100 mg/kg for
4 d, 60% of the mice challenged were protected from
infection, and the prepatent period of the nonprotected
mice was extended by 2 d over controls, indicating a
substantial reduction in the number of liver parasites [19].
Administration of the drug NCP-tazopsine at this fully
protective dose to animals inoculated with P. yoelii–infected
blood had no effect on blood stage parasite multiplication
(unpublished data). Analysis of female A. stephensi mosquitoes
fed on treated and untreated mice, revealed that NCP-
tazopsine had no effect on the transmissibility of the parasite
(unpublished data). These observations conﬁrmed that NCP-
tazopsine is only active against the hepatic phase of the life
cycle. This result was further conﬁrmed through quantiﬁca-
tion by real-time PCR, performed on RNA puriﬁed from the
livers of another group of mice challenged with a massive
sporozoite dose (120,000 parasites) and treated with NCP-
tazopsine. As compared to controls, parasite loads at 42 h PI
in the animals treated with the fully protective dose were
reduced by 99.98%, and those at the suboptimal dose by
98.58% (Figure 4C).
Discussion
We have described a naturally occurring morphinan,
tazopsine, that can be readily isolated in high yields (0.56%
w/w) from the stem bark of S. thouarsii. This compound
represents a novel class of antimalarial drugs and possesses
outstanding inhibitory activity against the Plasmodium hepatic
stages (Patents: Priority Europe No 04 291 055.4 April 22
2004; International Patent Application 21 April 2005 No
PCT/EP 2005/005239). Tazopsine represents one of the ﬁrst
Table 1. Comparative Inhibitory Activities of Tazopsine, NCP-Tazopsine, and Primaquine on Hepatic Stages Cultured in Primary
Hepatocytes
Drug P. yoelii P. falciparum
IC50 (lM) IC90 (lM) TC50 (lM) TI IC50 (lM) IC90 (lM) TC50 (lM) TI
Tazopsine 3.1 6 0.1 6.3 6 0.8 43.7 6 1.6 14 4.2 6 0.1 18.3 6 2.8 28.4 6 4.3 7
NCP-tazopsine 3.3 6 0.05 5.2 6 1.4 150.5 6 9.5 46 42.4 95.4 6 6.6 2,549.6 6 307.6 60
Primaquine 0.64 6 0.1 .30 70.5 6 4.3 110 0.80 6 0.9 4.1 6 0.5 65.2 6 11.9 81
doi:10.1371/journal.pmed.0030513.t001
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activity against the parasite’s hepatic stage.
Exposure to tazopsine prevented the in vitro development
of P. falciparum and P. yoelii, although with relatively low
therapeutic indices. The semisynthetic derivative NCP-tazop-
sine, prepared through simple amino alkylation, showed
substantially improved therapeutic indices in vitro and fully
protected mice against a large sporozoite challenge when
administered orally. The IC50 values and the therapeutic
indices of NCP-tazopsine do not differ substantially from
those of the licensed primaquine (Table 1). It is noteworthy
that the few chemical modiﬁcations of tazopsine attempted to
date have led to a compound, NCP-tazopsine, with signiﬁ-
cantly reduced toxicity and which have lost activity against P.
falciparum blood stages in vitro. It is likely that further
derivatizations, to which tazopsine is readily amenable, would
generate one or more compounds with improved pharmaco-
logical characteristics. Other morphinans, such as the opioids
morphine, codeine, and thebaine, were not found to be
inhibitory when tested against the P. yoelii liver stages (IC50 .
100 lM). Indeed these morphinans differed from tazopsine
and NCP-tazopsine mainly by the inverse absolute conﬁg-
uration of asymmetric carbons on the piperidine ring. It
would thus seem that the known targets of morphine-related
compounds are not implicated in the mechanism of action of
tazopsine and NCP-tazopsine, which remains at present
speculative. Classical biochemical and pharmacological in-
vestigations of Plasmodium liver stages are severely hampered
by the nonavailability of puriﬁed infected hepatocytes.
The urgent need to counter the emergence and global
spread of drug-resistant P. falciparum parasites has favored the
search for novel blood schizontocides to the detriment of
causal prophylactic agents. Furthermore, given the logistic
obstacles to screening compounds for activity against the
hepatic stage, namely the simultaneous availability of primary
hepatocytes and sporozoites, only a minor fraction of the
compounds screened for anti–asexual-stage activity are
assayed against the infected hepatocyte. Consequently, there
is a limited number of drugs effective against the Plasmodium
liver stage parasite. The deployment of primaquine, the only
drug speciﬁcally developed to inhibit the liver infection, has
been curtailed by the associated toxicity, poor compliance,
and increased risk of hemolysis when administered to persons
with glucose-6-phosphate dehydrogenase deﬁciency. This
latter problem will also affect the two related synthetic 8-
aminoquinolines, bulaquine [20] and tafenoquine [21],
presently undergoing clinical trials. Antifolates and atova-
quone, primarily used in combination to treat the blood stage
infection, were also shown to be active against the infected
hepatocyte. However, the high prevalence of resistant para-
sites to the former, and the ease with which resistance arises
to the latter, limit the prophylactic usefulness of these drugs.
Quinine, chloroquine, meﬂoquine, and artemisinin-based
compounds, have little or no efﬁcacy against the hepatic
parasite. Experimental compounds belonging to other chem-
ical classes, e.g., antibiotics [22], antihistaminics [23], or
Figure 2. Inhibitory Activity of Tazopsine on Plasmodium Hepatic Stages in vitro
(A) Representative curve of the dose-dependent inhibition of tazopsine (the number of parasite forms in test wells divided by the number of parasites in
control wells) for graph a, P. yoelii (filled squares [&], average number in control wells ¼ 274), and graph b, P. falciparum (filled circles [ ], average
number in control wells¼83). Toxicity as assessed by the neutral red assay is presented for graph c, mouse (open squares [&]), or graph d, human (open
circles [*]) primary hepatocytes. Results are means 6 standard deviation within triplicates of one experiment. R represents the factor of regression
calculated by SigmaPlot.
(B) Dose-dependent influence on the size of surviving P. falciparum hepatic forms, (21 forms were counted for each point, and the bar represents the
median value). Significance was calculated in one-way ANOVA analysis for the whole dataset (p , 0.0001), coupled to a Tukey HSD test: double asterisks
(**) indicate p , 0.01.
(C) P. falciparum hepatic forms (arrow) from cultures treated with tazopsine (15 lM) for 5 d, or untreated control cultures. DAPI staining is shown in the
right images, and P. falciparum–specific staining (anti-PfHSP70 antibodies) in the left images. N, hepatocyte nucleus. The bar represents 5 lm.
doi:10.1371/journal.pmed.0030513.g002
Figure 3. Susceptibility of Plasmodium Hepatic Stages to Tazopsine
during Growth
It should be noted that the in vivo duration of the hepatic phase of P.
yoelii is 44 to 48 h, whereas that of P. falciparum is just under 6 d.
(A) P. yoelii cultures were subjected to 3 lM (IC50; open bars) or 5 lM
(IC80; filled bars) of tazopsine for different periods of the development.
Preincubation of 80,000 sporozoites (Spz) in the presence of 5 lM or 100
lM of tazopsine for 1 h or 3 h, respectively, were carried out at room
temperature prior to washing and being added to the mouse primary
hepatocyte well.
(B) P. falciparum cultures were subjected to 4 lM (IC50; open bars) or 10
lM (IC80; filled bars) of tazopsine for different periods of development.
Inhibition was measured as the number of parasite forms in test wells
divided by the number of parasites in control wells, for P. yoelii, the
average number in control wells equaled 408, and for P. falciparum, 105.
Results are means 6 standard deviation.
doi:10.1371/journal.pmed.0030513.g003
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Alkaloids against Malaria Liver StagesFigure 4. Inhibitory Activity of NCP-Tazopsine on Plasmodium Hepatic Stages in vitro and Protective Activity of Tazopsine and NCP-Tazopsine for P.
yoelii Infections in vivo
(A) Representative curve of the dose-dependent inhibition of NCP-tazopsine (the number of parasite forms in test wells divided by the number of
parasites in control wells) for (graph a) P. yoelii (filled squares [&], average number in control wells¼152), and (graph b) P. falciparum (filled circles [ ],
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against the PE stages of Plasmodium. Most of these were tested
only on rodent malaria parasites and in which they were also
active against the blood stages. Two quinoline esters
prevented relapse of P. cynomolgi in monkeys [25], as did two
imidazolidinedione compounds prepared from the antifolate
chlorproguanil [26]. Although the ﬁrst had additional activity
against blood stage parasites, the two imidazolidinedione
molecules proved not to inhibit the erythrocytic stages of P.
berghei in mice nor those of P. falciparum in vitro [27]. The
hepatic stage speciﬁcity of the imidazolidinediones and NCP-
tazopsine places these lead molecules from two distinct
chemical classes into a novel category of antimalarial
compounds with true causal prophylactic activity.
Although tazopsine constitutes a suitable lead candidate
for further optimization, there are a number of issues that
would need to be addressed before it reaches the status of a
drug candidate. Toxicity is a very important parameter since
a drug aimed for prophylactic use will by deﬁnition be
administered over long periods of time. Two aspects of the
results are of some encouragement in this context. Deriva-
tives, such as NCP-tazopsine, that retain inhibitory activity
yet have signiﬁcantly reduced toxicity as compared to the
parent compound tazopsine, were readily obtained. The
recent development of high-throughput screening of drug
activity on Plasmodium hepatic stages [28] should enhance lead
optimization, and provide candidates for pharmaceutical
optimization (adsorption, distribution, metabolism and ex-
cretion [ADME]). Full protection from an in vivo challenge
was afforded by oral administration of NCP-tazopsine,
although it remains to be demonstrated that a similar route
of intake will be equally effective in primates. As compared to
blood schizontocides in which inhibitory activity is observed
in the low nM range, the lM concentrations of tazopsine and
NCP-tazopsine required for the inhibitory activity of hepatic
stages in vitro were relatively modest. The equivalent values
for primaquine (0.64 lM and 0.8 lM for the P. yoelii and P.
falciparum liver stages in vitro), were also close to 1 lM (Table
1). These high concentrations, relative to blood schizonto-
cides, might reﬂect the fact that the target of the drug is
found within the cells of the liver, a metabolically complex
and active organ in part devoted to detoxiﬁcation.
Historically, a primary aim of antimalarial drug research
has been to develop a true causal prophylactic. These efforts
were much diminished by the introduction of the remarkably
successful chloroquine after the second World War, although
the high rate of P. vivax relapses in military personnel
returning to the United States from Korea in the early 1950s
led to primaquine [29], a drug still primarily used to effect the
radical cure of P. vivax and P. ovale by preventing relapses due
to hypnozoites. The fact that all antimalarials used to date
with true prophylactic activity also inhibit the erythrocytic
stages precludes any consideration of mass administration.
This is because exposure of blood stage parasites, in which
cyclical multiplication leads to high parasite loads and the
persistence of millions of parasites in the human host for
many weeks or months, to subcurative drug concentrations
exerts substantial pressure that would lead to the selection
and dissemination of drug-resistant parasites. This exposure
to selective drug pressure constitutes a major impediment to
efforts aimed at developing novel causal prophylactic com-
pounds. A drug active solely against the liver stages would
exert only marginal selective pressure, since a single infective
bite leads to an average of a few dozen hepatic stage parasites
that usually persist for less than 2 wk, during which they
undergo a single multiplicative expansion. The deployment
of such a drug would be especially valuable in containing the
spread of the disease in areas of emerging or epidemic
malaria, and in residents subjected to seasonal transmission.
It would be the ideal choice for transient visitors to endemic
areas, such as displaced populations, tourists, and the
military. In populations residing in areas of higher endemic-
ity, the drug would help reduce the effective dose of
infectious sporozoites, even if deployment is suboptimal.
The consequences of modest reductions in hepatic stage
parasite numbers might have disproportionate beneﬁcial
consequences on malaria morbidity, as suggested by the
results of one of the Phase IIb trials of the anti-PE vaccine
RTS,S [30,31]. Moreover, administration of this type of drug
would not impede natural boosting of immune responses
against PE or erythrocytic stage parasites.
In conclusion, the discovery of molecules with exclusive
action against the hepatic phase of the life cycle lays the
foundations to re-evaluate causal prophylaxis as a tool that
can be incorporated in control strategies and enhance global
efforts to reduce the major burden exacted by malaria.
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Background. The parasite that causes malaria has quickly developed
resistance to many of the drugs that are commonly used to treat this
disease. As a result, new drugs and drug combinations are needed. In
some parts of the world where antimalarial drugs are failing due to
resistance, or are not available to everyone, people often turn to
traditional herbal remedies instead. These traditional plant remedies can
be a useful starting point for development of new drugs, but the process
of developing effective new drugs from plant remedies is long and
complicated. An important initial step is to isolate and identify the active
compounds from plants and then see how well these compounds
perform against malaria parasites in laboratory tests. If the tests are
successful, such compounds could then progress to experiments in
animals and possibly eventually human trials. One plant used widely in
Madagascar for treatment of malaria is Strychnopsis thouarsii; the
traditional remedy consists of the plant stem bark boiled in water.
Why Was This Study Done? The group of researchers doing this study
wanted to discover candidates for new malaria drugs. They therefore
wanted to find out which molecular compounds in the stem bark of S.
thouarsii contained antimalarial activity, and what particular stage of the
malaria parasite’s life cycle these compounds had an effect on. The
researchers suspected that the agents in this plant bark had some
activity against the ‘‘liver stage’’ of malaria infection in humans. This is
the first stage of infection, after a person has been bitten by a malaria-
infected mosquito, and before blood cells are invaded by malaria
parasites (which then causes the disease symptoms). Very few drugs
currently in existence have an effect on the ‘‘liver stage’’ of infection, but
activity at this stage would be tremendously useful because it could
mean a drug is better for prevention of malaria than others in existence.
What Did the Researchers Do and Find? First, the researchers wanted
to take the traditional herbal remedy—of S. thouarsii bark boiled in
water—and find out precisely which molecule in that remedy was
responsible for the antimalarial activity. They therefore used a method
called chromatography to progressively separate the herbal extract into
its distinct components. At each stage of separation, the extract was
checked for activity against malaria using a laboratory test. Inactive
extracts were disregarded, and the active component then taken on to a
further separation round. After many rounds of separation and testing,
the researchers got down to a single, apparently new, molecule that was
active against malaria in the laboratory test, and this molecule was
named tazopsine (in the Malagasy language the word Tazo refers to
malaria). In order to find out how effective the molecule was at killing
malaria parasites, the researchers took human or mouse liver cells
cultured in the laboratory, infected them with malaria parasites (either
the malaria parasite that normally infects humans, or a related species
that infects mice), and then added tazopsine at different concentrations.
The compound completely killed the malaria parasites even at very low
concentrations, and had activity against malaria infecting either liver cells
or red blood cells. Tazopsine was then given to mice injected with a
species of the malaria parasite. The compound protected most mice
against malaria infection when it was used at a dosage level lower than
the toxic dose. The researchers then tried making a series of different
variants of tazopsine in the hope that some variants would be less toxic,
but equally active as, the original compound. They found one variant,
named NCP-tazopsine, that was much less toxic but just as active as
tazopsine, but only against the malaria infecting liver cells.
What Do These Findings Mean? In these experiments a new molecule,
tazopsine, was discovered from a Malagasy plant, and it was found to be
active against liver-stage malaria parasites, in laboratory experiments and
in mice. This molecule or variants of it could in future become candidate
antimalarial drugs in humans. However, much work would need to be
done before testing could get to that stage. Different variants of
molecules related to tazopsine would need to be tested to find one that
has low toxicity, and these variants would need to be fully evaluated in
animals to see how they are handled in the body before any trials could
begin in humans.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030513
  The World Health Organization publishes a minisite containing links to
information about all aspects of malaria worldwide, including
treatment, prevention, and current programmes for malaria control
  Medicines for Malaria Venture is a collaboration between public and
private organizations (including the pharmaceutical industry) that
aims to fund and manage the development of new drugs for
treatment and prevention of malaria
  Wikipedia entries for drug discovery and drug development (note:
Wikipedia is an internet encyclopedia that anyone can edit)
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